Ripo, Zaphet Jay N.
HRN: 23-66-12 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/23/2023
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
10/23/2023
10/30/2023
IV
50MG
IV
PCAP C
Waiting Final Action
Indication: ProphylaxisEmpiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes